Le Lézard
Classified in: Health, Business
Subject: CXP

Hematogenix Announces the Opening of Their Newest Facility in Shanghai, China


TINLEY PARK, Ill., Dec. 19, 2019 /PRNewswire/ -- Hematogenix® announces the opening of their newest facility in Shanghai, China furthering their commitment to be a global leader in the field of cancer research and diagnostic testing. China's growing population is attractive to the pharmaceutical industry as the race to develop new therapies for the oncology market continues. The decision to invest in China's rapidly growing research and development market positions Hematogenix as a global contributor to the advancement of oncology research. Hematogenix is one of the companies that is responding to recent advancements that have occurred in China's clinical trials regulations.

Hematogenix® is a specialized CRO with a global presence focused on cancer research and diagnostics.

"Our decision to expand to China supports the global science community," said Hytham Al-Masri, M.D., CEO and Founder of Hematogenix. "This investment is in-line with our mission to make it possible for scientists to do world-class research globally.  The multinational pharma partners we support are starting to make China a priority. We are providing a solution to support their goals through our Pharma Services expansion which now includes four locations, the Americas, Europe, China and Asia-Pacific."

About Hematogenix

Hematogenix® is a specialized CRO with a global presence focused on cancer research and diagnostics. The company employs a team of top scientists, board-certified clinical, anatomic, and hematopathologists from around the world. Hematogenix offers an array of biomarker development and testing services which navigate the complexities of human subject clinical trials. The company's clinical laboratories are CAP, and CLIA certified, GCP-compliant and serve both the pharmaceutical industry as a specialized clinical research organization and the oncology industry as a clinical and anatomical testing provider. Learn more about Hematogenix's comprehensive biomarker development and testing services at www.hematogenix.com.

HEMATOGENIX® is a registered trademark of Hematogenix Laboratory Services, LLC.

Media Contact
Kathryn E. Evans
Phone: 708-444-0444
Email: [email protected]

SOURCE Hematogenix


These press releases may also interest you

at 09:50
Exegenesis Bio to Present 9-Patient Data from a Phase 1/2 Clinical Trial of EXG001-037, a Novel rAAV Gene Therapy for Spinal Muscular Atrophy (SMA) Type 1: Improved Head Control and Sitting Without External Assistance
Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American...

at 09:47
BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...

at 09:45
Pleio, Inc. and FountainRx Announce Partnership
Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty...

at 09:45
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech , a clinical stage pharmaceutical company with a...

at 09:41
Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in...

at 09:35
Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively. CancerVision and...

More news about Health...


News published on and distributed by: